In the past week, LLY stock has gone up by 0.47%, with a monthly gain of 0.77% and a quarterly plunge of -10.84%. The volatility ratio for the week is 2.28%, and the volatility levels for the last 30 days are 2.69% for Lilly(Eli) & Co The simple moving average for the past 20 days is 2.17% for LLY’s stock, with a -4.13% simple moving average for the past 200 days.
Is It Worth Investing in Lilly(Eli) & Co (NYSE: LLY) Right Now?
Lilly(Eli) & Co (NYSE: LLY) has a higher price-to-earnings ratio of 87.90x compared to its average ratio, The 36-month beta value for LLY is at 0.40. Analysts have varying views on the stock, with 15 analysts rating it as a “buy,” 7 rating it as “overweight,” 6 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LLY is 850.67M, and currently, shorts hold a 0.77% of that float. The average trading volume for LLY on December 10, 2024 was 3.60M shares.
LLY) stock’s latest price update
Lilly(Eli) & Co (NYSE: LLY)’s stock price has plunge by -2.80relation to previous closing price of 826.71. Nevertheless, the company has seen a 0.47% surge in its stock price over the last five trading sessions. prnewswire.com reported 2024-12-09 that Results from BRUIN CLL-321 show Lilly’s pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib prolonged the time to next treatment or death by a median of 23.9 months compared to 10.9 months in the control arm BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor INDIANAPOLIS, Dec. 9, 2024 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. The study’s primary endpoint of progression-free survival (PFS) was met at primary analysis1, demonstrating pirtobrutinib was superior to investigator’s choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR), based on independent review committee (IRC) assessment.
Analysts’ Opinion of LLY
Many brokerage firms have already submitted their reports for LLY stocks, with Wolfe Research repeating the rating for LLY by listing it as a “Outperform.” The predicted price for LLY in the upcoming period, according to Wolfe Research is $1000 based on the research report published on November 15, 2024 of the current year 2024.
Bernstein, on the other hand, stated in their research note that they expect to see LLY reach a price target of $1100. The rating they have provided for LLY stocks is “Outperform” according to the report published on October 17th, 2024.
Citigroup gave a rating of “Buy” to LLY, setting the target price at $1060 in the report published on September 13th of the current year.
LLY Trading at -4.67% from the 50-Day Moving Average
After a stumble in the market that brought LLY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.37% of loss for the given period.
Volatility was left at 2.69%, however, over the last 30 days, the volatility rate increased by 2.28%, as shares sank -3.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.45% lower at present.
During the last 5 trading sessions, LLY rose by +0.47%, which changed the moving average for the period of 200-days by +4.42% in comparison to the 20-day moving average, which settled at $786.53. In addition, Lilly(Eli) & Co saw 37.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LLY starting from Zakrowski Donald A, who proposed sale 900 shares at the price of $803.38 back on Nov 08 ’24. After this action, Zakrowski Donald A now owns shares of Lilly(Eli) & Co, valued at $723,042 using the latest closing price.
Zakrowski Donald A, the SVP, Finance, & CAO of Lilly(Eli) & Co, sale 900 shares at $803.38 during a trade that took place back on Nov 08 ’24, which means that Zakrowski Donald A is holding 5,480 shares at $723,042 based on the most recent closing price.
Stock Fundamentals for LLY
Current profitability levels for the company are sitting at:
- 0.35 for the present operating margin
- 0.82 for the gross margin
The net margin for Lilly(Eli) & Co stands at 0.2. The total capital return value is set at 0.28. Equity return is now at value 65.75, with 12.54 for asset returns.
Based on Lilly(Eli) & Co (LLY), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at 0.19. The debt to equity ratio resting at 2.19. The interest coverage ratio of the stock is 23.91.
Currently, EBITDA for the company is 8.57 billion with net debt to EBITDA at 2.22. When we switch over and look at the enterprise to sales, we see a ratio of 19.35. The receivables turnover for the company is 3.39for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.27.
Conclusion
In conclusion, Lilly(Eli) & Co (LLY) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
